Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer

Journal of the National Cancer Institute

Volumn 96, Issue 10, 2004, Pages 759-769

  Pegram, Mark D ^a   Pienkowski, Tadeusz ^b,c   Northfelt, Donald W ^a   Eiermann, Wolfgang ^b   Patel, Ravi ^a   Fumoleau, Pierre ^b   Quan, Eleonor ^a   Crown, John ^b   Toppmeyer, Deborah ^b   Smylie, Michael ^b   Riva, Alessandro ^b   Blitz, Sandra ^b   Press, Michael F ^d   Reese, David ^b   Lindsay, Mary Ann ^b   Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Breast Cancer International Research Group   (Canada)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUROSEMIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAGNESIUM; MANNITOL; NAVELBINE; PLATINUM DERIVATIVE; POTASSIUM; STEROID; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEARING LOSS; HEART DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; OTOTOXICITY; PANCYTOPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SEPSIS; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; BREAST TUMOR; CANCER STAGING; CHEMISTRY; GENE EXPRESSION REGULATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; SURVIVAL; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PLATINUM COMPOUNDS; RECEPTOR, ERBB-2; RESEARCH DESIGN; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 2942691785     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh133     Document Type: Article

References (75)

1. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23.
2. Fossati R, Confolonieri C, Torri V, Ghislandi E, Penna AQ, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-60.
3. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 2000;103:57-75.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
6. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-64.
7. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
8. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1998;16:1340-9.
9. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10:1044-8.
10. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
11. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
12. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;118:2241-51.
13. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
14. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38.
15. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000;27(6 Suppl 11:21-5.
16. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999;26(4 Suppl 12): 89-95.
17. Konecny G, Pegram MD, Beryt M, Untch M, Slamon DJ. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression [abstract]. Breast Cancer Res Treat 1999;57:114a.
18. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, et al. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994; 54:3758-65.
19. O'Donovan N, Beryt M, Duffy MJ, Crown J, Slamon DJ, Pegram M. HER-2/neu and apoptosis in breast cancer [abstract 2990]. Proc Am Assoc Cancer Res 2002;43:603.
20. Pegram MD, O'Callaghan C. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations. Clin Breast Cancer 2001;2 Suppl 1:S15-9.
21. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20: 1800-8.
22. Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 2001;21(2B):1301-5.
23. Burris HA 3rd. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Semin Oncol 2000;27(2 Suppl 3):19-23.
24. Burris HA 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28(1 Suppl 3):38-44.
25. Pegram MD. Docetaxel and Herceptin: foundation for future strategies. Oncologist 2001;6 Suppl 3:22-5.
26. Konecny G, Untch M, Slamon D, Beryt M, Kahlert S, Felber M, et al. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res Treat 2001;67:223-33.
27. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17:2341-54.
28. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999;17: 1413-24.
29. Crown J, Fumoleau P, Kerbrat P, Delecroix V, Borg-Olivieri O, Riva A, et al. Phase I trial of docetaxel (D) with cisplatin (P) as first-line chemotherapy of metastatic breast cancer (MBC) [abstract]. Proc ASCO 1997;16: 821a.
30. Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Casne A. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 1999;10:1457-60.
31. Pescia V, Bordenave HR, Foglia S, Litchvaky A, Wull F, Belloqui D, et al. Taxotere (T) and cisplatin (P) in anthracycline-pretreated advanced breast cancer (ABC): preliminary results [abstract]. Proc ASCO 2000;19:452a.
32. Antoine EC, Meric JB, Coeffic D, Khallel N, Auclerc G, Nizri D, et al. Anthracycline-primary resistant breast cancer (APRBC): confirmatory results of the high level of activity of the docetaxel (D)-cisplatin (C) regimen [abstract]. Proc ASCO 1999;18:491a.
33. Perez EA, Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000;88:124-31.
34. Loesch D, Robert N, Asmar L, Gregurich MA, O'Rourke M, Dakhil S, et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002;20:3857-64.
35. Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001;84:170-8.
36. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001;19:1901-5.
37. Aoki Y, Sato T, Tsuneki I, Watanabe M, Kase H, Fujita K, et al. Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer. Int J Gynecol Cancer 2002;12:704-9.
38. Belani CP; TAX 326 Study Group. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol 2002;29(3 Suppl 12):4-9.
39. Belani C; TAX 326 Study Group. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis. Semin Oncol 2001; 28(3 Suppl 9):10-4.
40. Laack E, Dierlamm T, Knuffmann C, Popp J, Schmied B, Durk H, et al. Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer 2002;36:303-7.
41. Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol 2002;29(3 Suppl 12):22-7.
42. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-49.
43. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
44. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
45. Donahue A, McCune JS, Faucette S, Gillenwater HH, Kowalski RJ, Socinski MA, et al. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. Cancer Chemother Pharmacol 2001;47:373-9.
46. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84:452-9.
47. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 1995;121:478-86.
48. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17: 2235-49.
49. Lopez AM, Pegram MD, Slamon DJ, Landaw EM. A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci U S A 1999;96:13023-8.
50. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
51. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605-11.
52. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cisdiamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575-80.
53. Nabholtz JM, Mackey JR, Smylie M, Paterson A, Noel DR, Al-Tweigeri T, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line therapy for metastatic breast cancer. J Clin Oncol 2001;19:314-21.
54. Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, et al. Multicenter phase II trial of weekly Navelbine plus Herceptin in chemonaive patients with HER2 positive metastatic breast carcinoma [abstract 1986]. Proc ASCO 2001;20:59b.
55. Theodoulou M, Campos S, Welles L, Baptist G, Winer E, Hudis C. Preliminary cardiac safety and efficacy data from a phase I/II trial of TLC D-99 (D-99) and trastuzumab (T) in patients (PTS) with locally advanced or metastatic breast cancer (LABC/MBC) [abstract 179]. Proc ASCO 2001;20:46a.
56. O'Shaughnessy J, Vukelja SJ, Marsland T, Kimmel G, Ratnam S, Pippen J. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer 2002;3 Suppl. 1:17-20.
57. Miller KD, Sisk J, Ansari R, Gize G, Nattam S, Pennington K, et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology 2001;15(2 Suppl 3):38-40.
58. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30.
59. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, Christodoulou CH, Timotheadou E, Kalofonos CH, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001; 12:1545-51.
60. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95.
61. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28(1 Suppl 3):13-9.
62. Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002;63 Suppl 1:57-63.
63. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002;29(3 Suppl 11):38-43.
64. Piccart-Gebhart MJ. Herceptin: the future in adjuvant breast cancer therapy. Anticancer Drugs 2001;12 Suppl 4:S27-33.
65. Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol 2001;28(5 Suppl 16):41-6.
66. Baselga J. Current and planned clinical trials with trastuzumab (Herceptin). Semin Oncol 2000;27(5 Suppl 9):27-32.
67. McNeil C. Herceptin in the adjuvant setting: phase III trials begin. J Natl Cancer Inst 2000;92:683-4.
68. Nabholtz JM, Reese DM, Lindsay MA, Riva A. HER2-positive breast cancer: update on Breast Cancer International Research Group Trials. Clin Breast Cancer 2002;3 Suppl 2:S75-9.
69. Mass R, Sanders C, Kasian C, Johnson L, Everett T, Anderson S. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization in the Herceptin pivotal trials [abstract 291]. Proc ASCO 2000;19:75a.
70. Uber KA, Nicholson BP, Thor AD, Merkel DE, Goldstein LJ, Gradishar WL, et al. A phase II trial of weekly docetaxel (D) and Herceptin (H) as first- or second-line treatment in HER2-overexpressing metastatic breast cancer [abstract 1949]. Proc ASCO 2001;20:50b.
71. Raab G, Brugger W, Harbeck N, Heidemann E, Schaller G, Wallwiener D, et al. Multicenter randomized phase II study of docetaxel (Doc) given q3w vs. q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer (MBC) [abstract]. Breast Cancer Res Treat 2002;76(Suppl 1):443.
72. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer [abstract 35]. Breast Cancer Res Treat 2002;76(Suppl 1):S37.
73. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-7.
74. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4.
75. Press MF, Sauter G, Bernstein L, Zhou J, Li B, Mirlacher M, et al. Comparison of HER-2/neu status determined by fluorescence in situ hybridization (FISH) in the BCIRG central laboratories with HER-2/neu status determined by immunohistochemistry or FISH in outside laboratories [abstract 238]. Proc SABCS 2002.